Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH
3 search results for:

Ensartinib 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 12-08-2020 | Non-small-cell lung cancer | News | Article
    WCLC Virtual Presidential Symposium 2020

    Ensartinib ‘a new first-line option’ for ALK-positive NSCLC

    The eXalt3 study has shown significantly better progression-free survival with ensartinib versus crizotinib in ALK inhibitor-naïve patients with ALK alteration-positive, advanced non-small-cell lung cancer.

    Author:
    Shreeya Nanda
    Published in:
    WCLC Virtual Presidential Symposium 2020: 8 August
  2. 08-11-2019 | Non-small-cell lung cancer | News | Article

    Ensartinib could expand treatment options for ALK-positive NSCLC

    At least half of patients with crizotinib-resistant ALK translocation-positive non-small-cell lung cancer respond to treatment with the new-generation ALK inhibitor ensartinib, including those with brain metastases, phase II study data show.

    Published in:
    Lancet Respir Med 2019; doi:10.1016/S2213-2600(19)30252-8
  3. 21-09-2018 | Non-small-cell lung cancer | News | Article

    Brigatinib has intracranial activity in patients with ALK-rearranged NSCLC

    All three of these next-generation ALK inhibitors – brigatinib, lorlatinib, and ensartinib – are being compared with crizotinib in treatment-naïve patients with ALK -positive disease, and we will have to see whether these agents extend PFS to the same degree in the first-line as they do in the second-line, continued Camidge.

    Published in:
    J Clin Oncol 2018; 36 : 2677–2679, 2693–2701
  • 1

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.